Omada Health (NASDAQ:OMDA) Price Target Cut to $18.00 by Analysts at BMO Capital Markets

Omada Health (NASDAQ:OMDA) had its target price reduced by BMO Capital Markets from $27.00 to $18.00 in a report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ price objective points to a potential upside of 28.39% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Barclays reduced their price objective on Omada Health from $22.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Omada Health in a research report on Thursday, January 22nd. Wells Fargo & Company began coverage on Omada Health in a research note on Thursday, January 8th. They issued an “equal weight” rating and a $17.00 price target for the company. Morgan Stanley cut their price objective on shares of Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Evercore increased their target price on shares of Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.50.

Omada Health Stock Performance

Shares of Omada Health stock traded up $0.42 during trading hours on Friday, reaching $14.02. The company’s stock had a trading volume of 3,632,202 shares, compared to its average volume of 1,274,141. Omada Health has a one year low of $10.28 and a one year high of $28.40. The company’s 50 day simple moving average is $14.07 and its 200 day simple moving average is $18.73. The stock has a market cap of $811.90 million and a P/E ratio of -56.08.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.12. The company had revenue of $75.85 million for the quarter.

Insider Activity

In other Omada Health news, President Wei-Li Shao sold 5,618 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $16.13, for a total value of $90,618.34. Following the completion of the sale, the president directly owned 69,079 shares of the company’s stock, valued at approximately $1,114,244.27. This represents a 7.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sean P. Duffy sold 230,479 shares of Omada Health stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.60, for a total transaction of $3,595,472.40. Following the completion of the transaction, the chief executive officer directly owned 126,644 shares in the company, valued at $1,975,646.40. This represents a 64.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 276,893 shares of company stock valued at $4,336,787 in the last ninety days.

Institutional Trading of Omada Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio acquired a new position in Omada Health in the third quarter worth approximately $38,000. Raymond James Financial Inc. acquired a new position in shares of Omada Health in the 2nd quarter worth $32,000. Bellevue Group AG grew its holdings in shares of Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock worth $5,567,000 after acquiring an additional 1,791 shares during the last quarter. Quarry LP acquired a new stake in shares of Omada Health during the fourth quarter worth $29,000. Finally, Barclays PLC lifted its holdings in shares of Omada Health by 14.6% during the fourth quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after purchasing an additional 1,888 shares during the last quarter.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 earnings beat and solid top?line — Omada reported $0.08 EPS vs. consensus (?$0.04) and $75.85M revenue for Q4, showing strong execution that likely underpins today’s buying. MarketBeat Q4 Results
• Positive Sentiment: Q4/FY highlights show rapid growth and improving profitability — company reported 58% Q4 revenue growth, 53% for the year, 55% member growth, positive net income in Q4 and positive adjusted EBITDA for the year, supporting a re?rating toward profitability. GlobeNewswire Results
• Positive Sentiment: New product launches expand addressable market — Omada launched GLP?1 Flex Care for employer customers and new GLP?1 and cholesterol programs, which could drive member growth and higher revenue per member without employers bearing drug costs directly. GLP?1 Flex Care Release
• Positive Sentiment: Management set a ~22% revenue growth target for 2026 — the company outlined a double?digit growth objective while launching new clinical offerings, reinforcing the growth story. Seeking Alpha Growth Target
• Positive Sentiment: Goldman Sachs reiterates Buy — Goldman maintained a Buy rating with a $26 price target, providing analyst support for the outlook. TipRanks / Goldman Sachs
• Neutral Sentiment: FY2026 revenue guidance in line with Street — Omada gave revenue guidance of $312M–$322M (consensus ? $312.2M), a range that mostly meets expectations and reduces surprise risk but offers limited upside. Guidance Details
• Neutral Sentiment: Earnings call and transcripts available for deeper color — investors can review the call to validate margin trajectory and member economics. Earnings Transcript (Yahoo)
• Negative Sentiment: Barclays cut its price target to $17 — a notable downward revision that adds near?term downside pressure relative to higher targets and could temper investor enthusiasm. AmericanBankingNews / Barclays PT
• Neutral Sentiment: Morgan Stanley lowered its PT to $30 but kept an Overweight rating — still represents significant upside vs. current levels, though the cut reduces prior upside expectations. Benzinga / Morgan Stanley

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.